Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ULKA NITIN VAISHAMPAYAN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1659318640
CMS profile
301351
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$145,554.60

130 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Bayer HealthCare Pharmaceuticals Inc. $49,557.47 44
Exelixis Inc. $40,829.85 43
E.R. Squibb & Sons, L.L.C. $12,573.41 8
GENZYME CORPORATION $12,289.00 3
PFIZER INC. $9,590.22 8
Merck Sharp & Dohme LLC $6,405.00 3
Gilead Sciences, Inc. $4,601.90 4
Alkermes, Inc. $3,012.42 7
Seagen Inc. $2,646.41 3
EISAI INC. $1,641.79 2
Aadi Bioscience, Inc. $1,500.00 1
Celgene Corporation $500.00 1
Telix Pharmaceuticals $173.42 1
Olympus America Inc. $133.72 1
AVEO Pharmaceuticals, Inc. $99.99 1

Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ULKA NITIN VAISHAMPAYAN

NPI 1659318640 · CMS profile ID 301351

Allopathic & Osteopathic Physicians / Internal Medicine

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659318640?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ULKA NITIN VAISHAMPAYAN, NPI 1659318640, CMS profile ID 301351. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659318640?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ULKA NITIN VAISHAMPAYAN, NPI 1659318640, CMS profile ID 301351. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659318640?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ULKA NITIN VAISHAMPAYAN, NPI 1659318640, CMS profile ID 301351, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–130 of 130 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1659318640?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

130 matching records · $145,554.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 130 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–130 of 130.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $107.1103/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932806003 CMS
Bayer HealthCare Pharmaceuticals Inc. $317.2003/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930598055 CMS
Bayer HealthCare Pharmaceuticals Inc. $18.0203/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930590737 CMS
Bayer HealthCare Pharmaceuticals Inc. $161.1003/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930597787 CMS
Bayer HealthCare Pharmaceuticals Inc. $45.9603/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930600649 CMS
Bayer HealthCare Pharmaceuticals Inc. $68.9403/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930602627 CMS
Bayer HealthCare Pharmaceuticals Inc. $9,776.0003/26/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930602717 CMS
Bayer HealthCare Pharmaceuticals Inc. $84.9903/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930604221 CMS
Bayer HealthCare Pharmaceuticals Inc. $32.0203/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930607571 CMS
Bayer HealthCare Pharmaceuticals Inc. $266.7303/25/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930598851 CMS
Bayer HealthCare Pharmaceuticals Inc. $161.1003/25/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930598919 CMS
Bayer HealthCare Pharmaceuticals Inc. $382.8203/25/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930601521 CMS
Bayer HealthCare Pharmaceuticals Inc. $35.0003/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930606607 CMS
Bayer HealthCare Pharmaceuticals Inc. $32.7603/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930592361 CMS
Bayer HealthCare Pharmaceuticals Inc. $73.1003/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930598655 CMS
Bayer HealthCare Pharmaceuticals Inc. $5,872.0003/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930604631 CMS
Bayer HealthCare Pharmaceuticals Inc. $26.0003/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930606383 CMS
Exelixis Inc. $4,290.0003/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932467343 CMS
Exelixis Inc. $84.7603/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932467345 CMS
Exelixis Inc. $1,201.0403/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932467347 CMS
Bayer HealthCare Pharmaceuticals Inc. $936.0003/17/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930604343 CMS
Gilead Sciences, Inc. $1,890.0003/10/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929448115 CMS
Bayer HealthCare Pharmaceuticals Inc. $709.4503/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930591339 CMS
Bayer HealthCare Pharmaceuticals Inc. $5,872.0003/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930597499 CMS
Bayer HealthCare Pharmaceuticals Inc. $147.0602/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930597741 CMS
Bayer HealthCare Pharmaceuticals Inc. $107.5302/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930597193 CMS
Bayer HealthCare Pharmaceuticals Inc. $96.6102/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930593373 CMS
Bayer HealthCare Pharmaceuticals Inc. $247.2101/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930593903 CMS
Bayer HealthCare Pharmaceuticals Inc. $247.2101/22/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930597201 CMS
Alkermes, Inc. $540.0001/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 925961439 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $302,012.55 267
PY2020 $129,776.04 86
PY2021 $88,841.20 53
PY2022 $145,554.60 130
PY2023 $154,682.18 143
PY2024 $103,779.26 90
PY2025 $70,927.41 68

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,820,888.06 74
PY2024 Recipient $25.00 1
PY2024 Principal investigator $10,301,924.71 51
PY2023 Principal investigator $2,387,740.53 37
PY2022 Principal investigator $1,700,819.53 71
PY2021 Principal investigator $7,985,377.84 27
PY2020 Recipient $15,317.15 9
PY2020 Principal investigator $1,526,375.55 317
PY2019 Principal investigator $5,013,042.51 755

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

74 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $33,180.00 12/31/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202427103
Principal investigator 1 Merck Sharp & Dohme LLC $49,705.26 12/31/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Phase 1 , Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan MK-6482 in Participants With Advanced Clear Cell Renal Cell Carcinoma ccRCC No dispute reported 06/30/2026 1232934872
Principal investigator 1 Genentech, Inc. $48,500.00 12/22/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Biology of Cancer Case-Control Study No dispute reported 06/30/2026 1211560282
Principal investigator 1 ABBVIE INC. $9,429.90 12/04/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202427038
Principal investigator 1 Coherus Oncology, Inc. $308.44 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253664
Principal investigator 1 Coherus Oncology, Inc. $138.68 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253670
Principal investigator 1 Coherus Oncology, Inc. $138.68 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253674
Principal investigator 1 Coherus Oncology, Inc. $173.51 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253678
Principal investigator 1 Coherus Oncology, Inc. $313.47 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253681
Principal investigator 1 Coherus Oncology, Inc. $175.44 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253685
Principal investigator 1 Coherus Oncology, Inc. $175.44 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253809
Principal investigator 1 Coherus Oncology, Inc. $313.47 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253814
Principal investigator 1 Coherus Oncology, Inc. $138.68 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253818
Principal investigator 1 Coherus Oncology, Inc. $166.41 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253823
Principal investigator 1 Coherus Oncology, Inc. $308.44 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253826
Principal investigator 1 Coherus Oncology, Inc. $173.51 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253830
Principal investigator 1 Coherus Oncology, Inc. $12,570.00 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253835
Principal investigator 1 Coherus Oncology, Inc. $329.60 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253838
Principal investigator 1 Coherus Oncology, Inc. $161.90 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253841
Principal investigator 1 Coherus Oncology, Inc. $157.38 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253845
Principal investigator 1 Coherus Oncology, Inc. $139.32 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253851
Principal investigator 1 Coherus Oncology, Inc. $309.28 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253855
Principal investigator 1 Coherus Oncology, Inc. $3,000.00 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253859
Principal investigator 1 Coherus Oncology, Inc. $304.44 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253864
Principal investigator 1 Coherus Oncology, Inc. $313.47 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253875
Principal investigator 1 Coherus Oncology, Inc. $138.68 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253879
Principal investigator 1 Coherus Oncology, Inc. $329.60 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253883
Principal investigator 1 Coherus Oncology, Inc. $139.32 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253888
Principal investigator 1 Coherus Oncology, Inc. $175.44 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253891
Principal investigator 1 Coherus Oncology, Inc. $173.51 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253896
Principal investigator 1 Coherus Oncology, Inc. $138.68 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253899
Principal investigator 1 Coherus Oncology, Inc. $313.47 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253903
Principal investigator 1 Coherus Oncology, Inc. $166.41 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253907
Principal investigator 1 Coherus Oncology, Inc. $157.38 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253911
Principal investigator 1 Coherus Oncology, Inc. $308.44 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253916
Principal investigator 1 Coherus Oncology, Inc. $161.90 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253919
Principal investigator 1 Coherus Oncology, Inc. $329.60 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253923
Principal investigator 1 Coherus Oncology, Inc. $157.38 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253928
Principal investigator 1 Coherus Oncology, Inc. $157.38 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253931
Principal investigator 1 Coherus Oncology, Inc. $161.90 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253935
Principal investigator 1 Coherus Oncology, Inc. $139.32 11/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253939
Principal investigator 1 ABBVIE INC. $18,637.28 11/05/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426968
Principal investigator 1 ABBVIE INC. $21,988.05 10/09/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426929
Principal investigator 1 Genentech, Inc. $291,034.00 10/09/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Biology of Cancer Case-Control Study No dispute reported 06/30/2026 1211560259
Principal investigator 1 Merck Sharp & Dohme LLC $92,513.28 08/31/2025 Non-covered Recipient Entity
University of Michigan
STUDY NAME#Phase II trial of Pembrolizumab and Lenvatinib in Advanced,metastatic Neuroendocrine Prostate Cancer PLANE-PC No dispute reported 06/30/2026 1232932291
Principal investigator 1 Merck Sharp & Dohme LLC $663,167.04 08/31/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Phase 1 , Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan MK-6482 in Participants With Advanced Clear Cell Renal Cell Carcinoma ccRCC No dispute reported 06/30/2026 1232935051
Principal investigator 1 Genentech, Inc. $166,874.74 08/22/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Biology of Cancer Case-Control Study No dispute reported 06/30/2026 1211560256
Principal investigator 1 ABBVIE INC. $3,918.38 08/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426850
Principal investigator 1 Genentech, Inc. $170,058.00 07/22/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Biology of Cancer Case-Control Study No dispute reported 06/30/2026 1211560240
Principal investigator 1 ABBVIE INC. $3,008.93 07/02/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426781
Principal investigator 1 ABBVIE INC. $10,001.37 07/02/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426785
Principal investigator 1 Genentech, Inc. $155,944.74 06/18/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Biology of Cancer Case-Control Study No dispute reported 06/30/2026 1211560146
Principal investigator 1 ABBVIE INC. $14,009.40 06/03/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426729
Principal investigator 1 Genentech, Inc. $172,132.00 05/22/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Biology of Cancer Case-Control Study No dispute reported 06/30/2026 1211560138
Principal investigator 1 ABBVIE INC. $19,200.36 05/07/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426685
Principal investigator 1 ABBVIE INC. $14,475.74 05/07/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426689
Principal investigator 1 Merck Sharp & Dohme LLC $39,108.00 05/05/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Phase 1 , Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan MK-6482 in Participants With Advanced Clear Cell Renal Cell Carcinoma ccRCC No dispute reported 06/30/2026 1232934870
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,126.00 04/16/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) No dispute reported 06/30/2026 1235999908
Principal investigator 1 Genentech, Inc. $134,335.00 04/14/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Biology of Cancer Case-Control Study No dispute reported 06/30/2026 1211560189
Principal investigator 1 ABBVIE INC. $2,610.96 04/03/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426622
Principal investigator 1 ABBVIE INC. $28,559.31 04/03/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426625
Principal investigator 1 Coherus Oncology, Inc. $568.75 03/21/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253867
Principal investigator 1 Coherus Oncology, Inc. $12,570.00 03/21/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
SRF388-101 No dispute reported 06/30/2026 1235253872
Principal investigator 1 Genentech, Inc. $106,348.00 03/20/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Biology of Cancer Case-Control Study No dispute reported 06/30/2026 1211560185
Principal investigator 1 Genentech, Inc. $123,597.87 03/20/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Biology of Cancer Case-Control Study No dispute reported 06/30/2026 1211560193
Principal investigator 1 ABBVIE INC. $15,007.86 03/07/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
M20-431 - A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426563
Principal investigator 1 ABBVIE INC. $16,002.45 03/07/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
M20-431 - A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426567
Principal investigator 1 Genentech, Inc. $117,576.61 02/20/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Biology of Cancer Case-Control Study No dispute reported 06/30/2026 1211560163
Principal investigator 1 ABBVIE INC. $199.95 02/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
M20-431 - A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426506
Principal investigator 1 ABBVIE INC. $397.97 02/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
M20-431 - A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426510
Principal investigator 1 Merck Sharp & Dohme LLC $1,049,286.00 02/05/2025 Non-covered Recipient Entity
Sentry Biopharma Services
Phase II trial of Pembrolizumab and Lenvatinib in Advanced,metastatic Neuroendocrine Prostate Cancer PLANE-PC No dispute reported 06/30/2026 1232932289
Principal investigator 1 Genentech, Inc. $121,001.87 01/28/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Biology of Cancer Case-Control Study No dispute reported 06/30/2026 1211560166
Principal investigator 1 Amgen Inc. $65,933.96 01/22/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors No dispute reported 06/30/2026 1246637770
Principal investigator 1 ABBVIE INC. $921.06 01/02/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
M20-431 - A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202426460